Novocure announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the U.S. Food and Drug Administration (FDA). The PMA application for LUNAR was submitted with a filing date of December 15, 2023, and is now under substantive review by the FDA. Novocure expects to receive a regulatory decision from FDA in second half 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.98 USD | +1.47% |
|
+7.15% | +20.43% |
Jul. 01 | NovoCure Limited(NasdaqGS:NVCR) dropped from Russell Midcap Growth Index | CI |
Jul. 01 | NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.43% | 1.93B | |
+75.69% | 12.57B | |
-24.14% | 7.4B | |
-4.48% | 5.95B | |
+5.70% | 5.05B | |
-14.67% | 4.95B | |
+19.72% | 4.29B | |
-16.42% | 4.12B | |
-16.19% | 3.16B | |
-0.87% | 2.01B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer